More on bevacizumab in hereditary hemorrhagic telangiectasia [11]

New England Journal of Medicine

Volumn 361, Issue 9, 2009, Pages 931-932

  Oosting, Sjoukje ^a   Nagengast, Wouter ^a   De Vries, Elisabeth ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ESTROGEN; IRON; TRANEXAMIC ACID; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ABSENCE OF SIDE EFFECTS; AGED; ANEMIA; ARTERIOVENOUS SHUNT; CASE REPORT; DRUG EFFICACY; EPISTAXIS; ERYTHROCYTE CONCENTRATE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IRON THERAPY; LETTER; LIVER TRANSPLANTATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; IMMUNOLOGY; NOTE; MALE; MIDDLE AGED;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; MALE; MIDDLE AGED;

EID: 69349096034     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc091271     Document Type: Letter

References (2)

1. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-2144
2. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313-1319